Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response. Combining
vaccine therapy with interleukin-12 and either alum or sargramostim may kill more tumor
cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of combining vaccine therapy
with interleukin-12 and either alum or sargramostim in treating patients who have undergone
surgery for stage II, stage III, or stage IV melanoma.